Aqsa Mazhar¹, Lubna Samad², Afza Naureen Ghouse³ and Yousuf Abd Mallick⁴*

¹Vascular Anomalies Centre, Indus Hospital and Health Network, Karachi, Sindh, Pakistan
²Interactive Research and Development (IRD) Global, Singapore city, Singapore
³Dermatology Unit, Indus Hospital and Health Network, Karachi, Sindh, Pakistan
⁴Dermatology Unit, Liaquat College of Medicine and Dentistry, Karachi, Sindh, Pakistan

*Corresponding Author: Yousuf Abd Mallick, Assistant Professor and Section Head of Dermatology Unit, Liaquat College of Medicine and Dentistry, Karachi, Sindh, Pakistan.

Received: October 25, 2023; Published: November 20, 2023

Lymphatic malformations (LM) are an uncommon group of benign vascular anomalies with equal frequency in both sexes and incidence of 1 in 6000 to16,000 live births [1]. LM have predilection for head and neck region due to abundance of lymphatic glands [2]. Half of the LM cases are apparent at birth while almost 90% become symptomatic within two years [3]. Complications depend upon extent, severity, and type of LM, anatomic location and internal organs involvement. Traditionally, LM is divided in to macrocystic, microcystic and mixed types. Conventional treatments for macrocystic variant include sclerotherapy, debulking procedures and surgical excision, but none of these is effective against microcystic group [4].

References

1. Hyvönen H., et al. “Long-term outcomes of lymphatic malformations in children: an 11-year experience from a tertiary referral center”. Journal of Pediatric Surgery12 (2022): 1005-1010.
2. Ghaffarpour N., et al. “Surgical excision is the treatment of choice for cervical lymphatic malformations with mediastinal expansion”. Journal of Pediatric Surgery9 (2018): 1820-1824.
3. Waner M and Teresa MO. “Multidisciplinary approach to the management of lymphatic malformations of the head and neck”. Otolaryngologic Clinics of North America1 (2018): 159-172.
4. Tu JH., et al. “Long-term follow-up of lymphatic malformations in children treated with Sildenafil”. Pediatric Dermatology5 (2017): 559-565.
5. Swetman GL., et al. “Sildenafil for severe lymphatic malformations”. The New England Journal of Medicine 366 (2012): 384-386.
6. Liu X., et al. “Recent progress in lymphangioma”. Frontiers in Pediatrics 9 (2021): 735832.
7. Wnag S., et al. “Efficacy and safety of oral sildenafil in treatment of pediatric head and neck lymphatic malformations”. Acta Oto-Laryngologica6 (2017): 674-678.
8. Koshy JC, et al. “Sildenafil for microcystic lymphatic malformations of the head and neck: a prospective study”. International Journal of Pediatric Otorhinolaryngology7 (2015): 980-982.
9. European Medicines Agency. Revatio. Netherlands: European Union agencies network (2009).
10. Danial C., et al. “An open-label study to evaluate sildenafil for the treatment of lymphatic malformations”. Journal of American Academy of Dermatology 6 (2014): 1050-1057.

Citation

Citation: Yousuf Abd Mallick., et al. “Treatment of Microcystic Lymphatic Malformation with Oral Sildenafil Suspension in Paediatric Age Group”.Acta Scientific Medical Sciences 7.12 (2023): 38-41.

Copyright

Copyright: © 2023 Yousuf Abd Mallick., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.